Mesa and Gerds Talk Management Strategies and Emerging Agents in Myelofibrosis

Partner | Cancer Centers | <b>UT Health San Antonio MD Anderson Cancer Center</b>

Dr. Mesa and Dr. Gerds provide insight into the current utility of JAK inhibitors in myelofibrosis, unmet needs, and novel agents and combination strategies in the pipeline.

Welcome to OncLive On Air! I’m your host today, Caroline Seymour.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Sierra Oncology, we passed the mic to Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center and Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, to discuss the current landscape of myelofibrosis and key takeaways from the 2020 ASH Annual Meeting and Exposition for the field.

In our exclusive interview, Mesa and Gerds provided insight into the current utility of JAK inhibitors in myelofibrosis, unmet needs, and novel agents and combination strategies in the pipeline.